FMTX News and Press, Forma Therapeutics Holdings Inc. From 12/08/20

Forma Therapeutics ([[FMTX]] +2.9%) gains while competitor Agios Pharmaceuticals slides, after the pair presented updated data for their sickle cell disease candidates at the annual ASH meeting.FMTX’s FT-4202 data suggest a best-in-class asset as hemoglobin response rate was higher tha...

6 of 7 (86%) patients on 300 mg of FT-4202 for 14 days achieved a hemoglobin increase > 1 g/dL from baseline Hemolytic markers support the hypothesis that FT-4202 improves red blood cell survival and reduces turnover A favorable tolerability profile was observed aft...

Forma Therapeutics (FMTX): Q3 GAAP EPS of -$0.67 beats by $0.01.Cash, cash equivalents and marketable securities of $384.3M.Press Release For further details see: Forma Therapeutics EPS beats by $0.01

Strong pipeline progress amid challenging COVID-19 environment Oral presentation of MAD1 results at upcoming 2020 ASH Virtual Annual Meeting from the randomized, placebo-controlled multi-center Phase 1 trial evaluating FT-4202 in people with sickle cell disease MAD2 co...

The European Commission has designated Orphan Drug tag to Forma Therapeutics' (FMTX) FT-4202 for the treatment of sickle cell disease ((SCD)). The product candidate was previously granted Fast Track, Rare Pediatric Disease and Orphan Drug designations in the U.S. for SCD.The designation provi...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the European Commission granted Orphan Drug designation to Forma’s FT-4202 for the treatment of sickle cell disease (...

Updated data from an ongoing randomized, multi-center, placebo-controlled Phase 1 clinical trial of FT-4202 in sickle cell disease selected for an oral presentation Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on ra...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that company management will participate in three upcoming investor conferences. The Credit Suisse 29 th Annual He...

AC Immune suffers setback on Alzheimer’s front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer. Forma Therapeutics reports positive topline data from Phase 2 Olutasidenib trial. For further details see: AC Immune's Alzheimer's Setback,...

Forma Therapeutics Holdings (FMTX) announces positive preliminary data from a planned interim analysis of a Phase 2 clinical trial evaluating olutasidenib (FT-2102) in patients with isocitrate dehydrogenase 1 ((IDH1)) mutation-positive acute myeloid leukemia ((AML)).Patients receivi...